Key result
The STREAM-2 investigators provided a response to a letter regarding their trial comparing half-dose tenecteplase to primary percutaneous coronary intervention in older patients with STEMI.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Response clarifies STREAM-2 concerns; leaves open optimal reperfusion strategy in older STEMI patients.
status: Published
No takes yet. Share an insight, caveat, or question.
Werf et al. (2024) studied this question. The STREAM-2 investigators provided a response to a letter regarding their trial comparing half-dose tenecteplase to primary percutaneous coronary intervention in older patients with STEMI.
Synapse has enriched 10 related papers. Consider them for comparative context: